Skip to main content

Fam-Trastuzumab Deruxtecan-nxki

(fam-tras-TOO-zoo-mab DEH-rux-TEE-kan)

This page contains brief information about fam-trastuzumab deruxtecan-nxki and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Enhertu
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Fam-trastuzumab deruxtecan-nxki is approved to treat:

  • Breast cancer that is HER2 positive and cannot be removed by surgery or has metastasized (spread to other parts of the body). It is used in adults who have already received at least two anti-HER2 treatments for metastatic disease.

This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that fam-trastuzumab deruxtecan-nxki provides a clinical benefit in these patients.

Fam-trastuzumab deruxtecan-nxki is also being studied in the treatment of other types of cancer.

More About Fam-Trastuzumab Deruxtecan-nxki

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

For Metastatic HER2-Positive Breast Cancer, New Treatments Emerge

Targeted Cancer Therapies

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Fam-trastuzumab Deruxtecan-nxki - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: